News and events

In 2025 we celebrate HMGBiotech 20th anniversary, reaffirming our commitment towards innovation and dedication to advancing biomedical research.

2025 marks the 20th anniversary of HMGBiotech — a milestone that reflects two decades of innovation, collaboration, and dedication to advancing biomedical research.

Researches on High Mobility Group Box 1 (HMGB1) focus on its mediator role in fibrotic disease, and recent findings shed light on HMGB1 critical role in epithelial-mesenchymal transition (EMT) and pulmonary fibrosis associated with silicosis.

As we mark World Autoimmune Arthritis Day, occurring on 20th May, it is critical to highlight the molecular underpinnings that drive chronic pain and inflammation in autoimmune joint diseases such as rheumatoid arthritis (RA).

HMGB1 release is a hallmark of pyroptosis, distinguishing it from non-inflammatory death pathways. Once released, HMGB1 binds to receptors like RAGE and TLR4.

At HMGBiotech, we offer an integrated Custom Protein Production & Engineering service tailored to the evolving needs of academic researchers, biotech startups, and pharmaceutical developers.

A particularly innovative aspect of the study involved investigating the role of extracellular HMGB1 in dendritic cell-mediated T cell polarization.

Among the most compelling areas of investigation is the intersection between gut microbiota, neuroinflammation, and the multifunctional protein HMGB1 (High Mobility Group Box 1).

HMGB1 actively contributes to immune signaling and plays a significant role in thromboinflammatory disorders such as sickle cell disease (SCD).